4 results for “Biologics”
Houston’s BMS win will spark competing Texas incentive bids as other pharma firms hunt flexible ADC and biologics capacity.
This is a concrete reshoring-and-scale signal: big pharma is placing large, flexible capacity bets in the U.S. to support late-stage development through launch, with Texas positioning itself as a life-sciences manufacturing hub.
Texas will market the BMS win to lure another top-10 pharma manufacturing project into Houston’s Generation Park.
A multi-modality plant signals where big pharma is placing long-horizon capacity bets—especially for biologics and ADCs—while states compete with incentives.
Texas will market BMS’s Generation Park win to lure another top-10 pharma plant announcement before 2027 construction ramps.
A top-tier pharma manufacturer is placing flexible, multi-modality capacity in Texas—an industrial bet on domestic supply resilience and next-generation modalities like ADCs.
Innovent will push VANFLYTA deeper into China’s AML market as Daiichi Sankyo supplies the drug.
This is a meaningful China oncology commercialization move for both companies and a direct access story for a high-risk AML population.
You're all caught up · last 5 days